HMNC Holding GmbH: HMNC Brain Health and Develco Pharma Anno

Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,

Related Keywords

Germany , Australia , Pratteln , Switzerland General , Switzerland , Munich , Bayern , Zurich , Züsz , South Africa , Schopfheim , Baden Wüberg , German , Swiss , Michael Colla , Martin Renner , Anne Donohoe , Hans Eriksson , Alexander Schmidt , Erich Seifritz , Develco Pharma , Tim Regan Sophia Bashford , Kostenloser Wertpapierhandel , Ketabon Program , Psychiatric University Hospital Zurich , Holding Gmb , University Of Basel , Brain Health , Department Of Psychiatry , University Of Zurich , Clinical Development , Depression Rating Scale , Treatment Resistant Depression , Clinician Administered Dissociative States Scale , Chief Clinical Development Officer , Professor Erich Seifritz , Psychiatric University Hospital , Major Depressive Disorder , Scientific Advisory Board , Major Depression , Hmnc , Molding , Mbh , Rain , Health , Evelco , Dharma , Nnounce , Romising , Reliminary , Results , Treatment , Resistant , Depression , Asuggesting , Antidepressant , Efficacy , Showing , Placebo , Level , Dissociative ,